WO2019221769A1 - Enrichissement et détection de méthylation spécifique à une séquence - Google Patents

Enrichissement et détection de méthylation spécifique à une séquence Download PDF

Info

Publication number
WO2019221769A1
WO2019221769A1 PCT/US2018/054188 US2018054188W WO2019221769A1 WO 2019221769 A1 WO2019221769 A1 WO 2019221769A1 US 2018054188 W US2018054188 W US 2018054188W WO 2019221769 A1 WO2019221769 A1 WO 2019221769A1
Authority
WO
WIPO (PCT)
Prior art keywords
sample
target
dna
target region
nucleic acid
Prior art date
Application number
PCT/US2018/054188
Other languages
English (en)
Inventor
Anthony P. Shuber
Original Assignee
Genetics Research, Llc, D/B/A Zs Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/018,926 external-priority patent/US20190002964A1/en
Application filed by Genetics Research, Llc, D/B/A Zs Genetics, Inc. filed Critical Genetics Research, Llc, D/B/A Zs Genetics, Inc.
Priority to CA3100492A priority Critical patent/CA3100492A1/fr
Priority to EP18919343.6A priority patent/EP3794139A4/fr
Publication of WO2019221769A1 publication Critical patent/WO2019221769A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Definitions

  • the invention relates to molecular genetics.
  • a blood sample is obtained from a patient and may be centrifuged to remove whole blood cells, leaving plasma or serum that includes cell-free DNA (cfDNA).
  • the sample must be subject to a sample preparation protocol before any genetic analysis is performed.
  • laboratory technicians use a commercially-available kit to aliquot the serum through a series of steps that use proteinase solutions to digest away proteins, lysis buffers to dissociate vesicles and other lipid fragments, and cleaning and suspension buffers.
  • the resultant mixture is washed through a membrane within a column under vacuum after which the cfDNA is eluted from the column with a specialty wash buffer. The entire process can require hours or more and the use of expensive kits.
  • Methylation is the most studied epigenetic change and has been linked to cancer and certain metabolic disorders. Methylation is a chemical modification of DNA in which a methyl group is added to certain cytosines in DNA to yield 5-methylcytosine, Methylation appears to influence gene expression by affecting the interactions of both chromatin proteins and specific transcription factors with DNA.
  • hypermethylation or hypomethylation of a specific region of DNA is associated with cancer. The detection of, for example, hypermethylation in regions associated with cancer provides a useful approach to early detection.
  • Methylation is not the only epigenetic change that has been associated with disease.
  • Histone modification, chromatin rearrangement, and RNA silencing are examples of other epigenetic modifications that can have an impact on health and disease. Since epigenetic changes may be good diagnostic markers for disease, there remains a need for rapid and simple targeted detection.
  • the present invention provides methods for detecting epigenetic changes, including but not limited to methylation changes, in DNA directly from biological samples without the need for significant sample preparation steps or kits.
  • Methods of the invention use Cas endonuclease to bind target regions of DNA suspected to be affected by epigenetic changes.
  • Cas endonuclease is complexed with one or more guide RNAs that bind to protospacer adjacent motif (PAM) sequences near a region of interest, such as a methylation locus known to be associated with cancer, when hypermethylated.
  • PAM protospacer adjacent motif
  • the Cas endonuclease binds to and protects target regions of DNA even when a target DNA is only present as a small fraction of the sample.
  • methods of the invention are useful when analyzing DNA present in low abundance in a sample such as blood or other bodily fluids.
  • Cas proteins along with their sequence-specific guide RNAs (gRNA), are complexed and introduced directly into the biological sample.
  • the Cas/guide RNA complex may be introduced as part of sample collection, or added into collection tubes containing the sample.
  • the gRNA mediates binding of the Cas proteins to a target region of DNA of interest, such as a tumor DNA fragment suspected to be hypermethylated.
  • the target region is enriched relative to other materials in the sample by any suitable enrichment methods, such as by elution of bound Cas proteins.
  • the target region may be enriched by elimination of non-target DNA acid using, for example, exonucleases. Enrichment methods may be used alone or in combination with other enrichment methods.
  • the sample is enriched by isolating complex-bound target regions by amplification, size fractionation, or hybrid capture.
  • exonuclease digestion may be used alone, or may be used before or after elution of bound Cas proteins.
  • Epigenetic modifications are detected using available methods. For example, for methylation, one can use antibody binding, immunoassay, amplification, or gel electrophoresis, or other techniques known in the art. Detection of DNA methylation in the target region is indicative of increased risk, or even presence, of cancer.
  • Methods and related kits described herein are useful to detect the presence of methylation in a sample. Due to the nature by which a protein, such as a Cas complex, binds nucleic acid, methods may be used even where the target is present only in very small quantities, e.g., even as low as 0.01% frequency of mutant fragments among normal fragments in a sample (i.e., where about 50 copies of a circulating tumor DNA fragment harboring hypermethylation sites are present among about 500,000 unrelated fragments of similar size).
  • methods of the invention may have particular applicability in discovering very rare, yet clinically important, information, such as site-specific methylation of tumor related genes and may be used to detect abnormal methylation within cell-free DNA, such as target region-specific hypermethylation in circulating tumor DNA.
  • CRISPR/Cas systems and associated guide RNAs are introduced to a biological sample.
  • Cas endonuclease whether catalytically active or inactive— will bind to a target consistently via a guide RNA and will protect that target (i.e., stay bound), thereby allowing the target to be pulled out of the sample by, for example, elution of the captured sequence or elimination of non-target DNA.
  • the invention provides methods for detecting hypermethylation of a target region of DNA. Methods include obtaining a biological sample from a subject, introducing Cas proteins and guide RNA into the sample, and binding the Cas proteins to ends of a target region of DNA.
  • the Cas protein may be a Cas endonuclease or a catalytically deficient homolog thereof.
  • the target region is then enriched by isolating the target region from the sample.
  • the target region may be any naturally-occurring or artificial DNA.
  • the nucleic acid may be any naturally-occurring or artificial nucleic acid.
  • the nucleic acid may be DNA, RNA, hybrid DNA/RNA, peptide nucleic acid (PNA), morpholino and locked nucleic acid (LNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), or Xeno nucleic acid.
  • the RNA may be a subpopulation of RNA, such as mRNA, tRNA, rRNA, miRNA, or siRNA.
  • the nucleic acid is DNA.
  • the target region or feature of interest may be any site of epigenetic modification that is indicative of disease, such as a nucleic acid modification, a histone modification, or chromatin remodeling.
  • An example of a nucleic acid modification may be a modification to methylation status of DNA.
  • a feature of interest may be DNA hypermethylation or hypomethylation.
  • the methods of the invention involve the detection of DNA
  • the target may be from a sub-population of nucleic acid within the nucleic acid sample.
  • the target may contain cell-free DNA, such as cell-free fetal DNA or circulating tumor DNA.
  • the sample includes plasma from the subject and the target is cell-free DNA (cfDNA).
  • the plasma may be maternal plasma and the target may be of fetal DNA.
  • the sample includes plasma from the subject and the target is circulating tumor DNA (ctDNA).
  • the sample includes at least one circulating tumor cell from a tumor and the target is tumor DNA from the tumor cell.
  • the target is complementary DNA (cDNA), which is made by reverse transcribing RNA.
  • detecting cDNA is a way to detecting target RNA.
  • the target may be from any source of DNA.
  • the target is DNA from a biological sample from a human or other animal.
  • the biological sample is a body fluid sample, such as bile, blood, plasma, serum, sweat, saliva, urine, feces, phlegm, mucus, sputum, tears, cerebrospinal fluid, synovial fluid, pericardial fluid, lymphatic fluid, semen, vaginal secretion, products of lactation or menstruation, amniotic fluid, pleural fluid, rheum, vomit, or the like.
  • the biological sample is a blood sample, serum sample, plasma sample, urine sample, saliva sample, semen sample, feces sample, phlegm sample, or liquid biopsy.
  • the biological sample may be a tissue sample from an animal, such as skin, conjunctiva, gastrointestinal tract, respiratory tract, vagina, placenta, uterus, oral cavity or nasal cavity.
  • the biological sample may be a liquid biopsy or a tissue biopsy.
  • obtaining the sample includes obtaining a biological sample from a subject in a collection tube.
  • the biological sample is blood and the collection tube is centrifuged to isolate serum or plasma from blood cells.
  • the Cas endonuclease or catalytically deficient homolog thereof is introduced into the serum or plasma.
  • the Cas endonuclease, or the catalytically deficient homolog thereof is complexed with the guide RNA and introduced into the serum or plasma.
  • the Cas endonuclease, or the catalytically deficient homolog thereof is introduced into the serum or plasma as a ribonucleoprotein (RNP) in which the endonuclease is complexed with the guide RNA.
  • RNP ribonucleoprotein
  • the guide RNA includes at least two single guide RNA molecules that each complex with a Cas endonuclease, where the complexes target PAM sequences that are adjacent a target region and the guide RNA guides Cas endonuclease to hybridize to one of the targets, wherein the target region includes a methylation site associated with cancer when
  • the method may include enriching the sample by isolating the complex -bound target region from some or all of the unbound DNA.
  • the method may include binding the complex-bound target region to a particle.
  • the particle may include magnetic or paramagnetic material.
  • the method may include applying a magnetic field to the sample.
  • the particle may include an agent that binds to a protein bound to an end of the target DNA.
  • the agent may an antibody or fragment thereof.
  • the method may include chromatography, applying the sample to a column, or gel electrophoresis.
  • the method may include separating the complex-bound target from some or all of the unbound nucleic by size exclusion, ion exchange, or adsorption.
  • Each of the proteins may independently be any protein that binds a nucleic acid in a sequence-specific manner.
  • the protein may be a programmable nuclease.
  • the protein may be a CRISPR-associated (Cas) endonuclease, zinc-finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or RNA-guided engineered nuclease (RGEN).
  • the protein may be a catalytically inactive form of a nuclease, such as a programmable nuclease described above.
  • the protein may be a transcription activator- like effector (TALE).
  • the protein may be complexed with a nucleic acid that guides the protein to an end of the nucleic acid.
  • the protein may be a Cas endonuclease in a complex with one or more guide RNAs.
  • the protein is a Cas endonuclease or a catalytically deficient homolog thereof.
  • the Cas endonuclease is in a complex with one or more guide RNAs.
  • the target region may be detected by ligand binding assay, DNA staining, spectrophotometry, sequencing, fluorescent probe hybridization, fluorescence resonance energy transfer, optical microscopy, or electron microscopy.
  • Methods of the invention may include detecting and quantifying the DNA methylation of the target region. Detecting and quantifying the DNA methylation of the target region may include ligand binding assays, immunosorbent assays, such as enzyme-linked immunosorbent assay (ELISA), or other signal amplification techniques. In certain embodiments, the methods include quantifying relative amounts of hypermethylation of the target region.
  • the target is DNA and includes hypermethylation specific to a tumor.
  • the target is nucleic acid and includes a mutation specific to a tumor.
  • the target may be present at no more than about 0.01% of cell-free DNA in the plasma or serum.
  • the target is enriched by isolating the target from the serum or plasma.
  • Cas endonuclease may be provided with one or more guide RNAs that targets and binds to one or more target regions of DNA, such as a region or locus suspected to be hypermethylated.
  • the Cas endonuclease/guide RNA complex targets and binds to a target nucleic acid and flanks a loci of interest, such as a locus of a known cancer-associated mutation or a specific genetic allele of clinical interest.
  • the Cas endonuclease binds to, and protects, DNA containing hypermethylated sites even when the mutation is only present as a small fraction of the sample.
  • the Cas endonuclease binds to, and protects mutation- containing nucleic acid even when the mutation is only present as a small fraction of the sample.
  • the bound Cas proteins prevent exonuclease from digesting the target and, after incubation with exonuclease, the only nucleic acid substantially present in the sample is that of the target.
  • the target is thus isolated or enriched in a sequence- specific manner.
  • the target may then be subject to any suitable detection or analysis assay such as antibody signal or immunosorbent assays.
  • CRISPR/Cas systems using guide RNAs specific for a methylation site is introduced to the sample under conditions such that DNA containing the methylation site is protected from exonuclease digestion while non-target DNA is digested by an exonuclease.
  • Cas endonuclease—whether catalytically active or inactive— will bind to a target consistently via a guide RNA and will protect that target (i.e., stay bound) for at least long enough that a promiscuous exonuclease can be reliably used to digest unbound, non-target DNA.
  • a sample is effectively enriched for the target, and those remaining target fragments are captured, stored, isolated, preserved, detected, sequenced, or otherwise assayed with success that would be unobtainable without methods of the invention.
  • CRISPR/Cas systems using guide RNAs specific for a mutation is introduced to the sample under conditions such that nucleic acid containing the mutation is protected from exonuclease digestion while non-target nucleic acid is digested by an exonuclease.
  • Cas endonuclease—whether catalytically active or inactive— will bind to a target consistently via a guide RNA and will protect that target (i.e., stay bound) for at least long enough that a promiscuous exonuclease can be reliably used to digest unbound, non-target nucleic acid.
  • the invention provides a method for detecting a target nucleic acid.
  • the method includes obtaining a serum or plasma sample from a subject, introducing Cas proteins and guide RNA into the serum or plasma, and binding the Cas proteins to ends of a target nucleic acid.
  • the Cas protein may be a Cas endonuclease or a catalytically deficient homolog thereof.
  • Unbound nucleic acid is digested from the sample by introducing exonuclease while the Cas proteins prevent the exonuclease from digesting the target nucleic acid, thereby enriching the sample for the target nucleic acid.
  • the target nucleic acid may then be isolated from the enriched sample by amplification, size fractionation, or hybrid capture. Methods may include inactivating the exonuclease (e.g., by heating) prior to the isolating step.
  • two Cas proteins bind to ends of the target nucleic acid and prevent the exonuclease from digesting the target nucleic acid.
  • the invention provides a method for detecting methylation in DNA.
  • the method includes obtaining a biological sample, exposing the biological sample to a Cas /guide RNA complex.
  • the Cas protein may be a Cas endonuclease or a catalytically deficient homolog thereof.
  • the complex targets and binds to one or more target regions of DNA suspected to be hypermethylated in the sample.
  • the complexes are targeted to PAM sequences that are adjacent a target region of DNA suspected to be hypermethylated in the sample.
  • the sample may be enriched by isolating the target DNA by amplification, size fractionation, and hybrid capture.
  • the sample may be enriched by digesting the unbound DNA by introducing exonuclease while the Cas proteins prevent the exonuclease from digesting the target region, thereby enriching the sample for the target region DNA.
  • methods may include inactivating the exonuclease (e.g., by heating) prior to isolating the target DNA.
  • FIG. 1 shows a table of the inputs and the dilation amounts used in the Example described herein.
  • Dilution 11 is at 3x concentration from previous experiments because the experiment uses 3x as much input DNA volume in the reaction.
  • the copies per ul of stock, copies per ul in 50 ul reaction, amount of previous dilution (ul), plasma, and total volume (ul) are indicated.
  • FIG. 2 shows a table of the dilutions used in the Example. For the percent of plasma in the final reaction, the percent of plasma in 2x sample, plasma dilution (ul), and tris dilution (ul) are shown in the table.
  • FIG. 3 shows a graph of the qPCR results after amplification from the post-cutting dilutions described in the Example.
  • FIG. 4 shows the tabulated qPCR results from the Example. Percent plasma, use of a Streck tube, amount of no Cas9 present, amount of Cas9 present, and percent cutting are indicated.
  • FIG. 5 shows a chart of the binding efficiency from the Example, particularly showing the relationship between percent cleavage and percent plasma.
  • percent cleavage is shown as a function of the amount or percent of plasma in the cutting reaction. Results are shown for samples with no tube and samples using a Streck tube.
  • FIG. 6 shows a chart of the detection signal in plasma from the Example, particularly showing the relationship between qPCR signal and percent plasma.
  • the percent detection of no plasma in the sample is shown as a function of the percent plasma in the cutting reaction. Results are shown for samples with no tube and sample using a Streck tube.
  • Methods of the invention provide for the enrichment of a target nucleic acid, in a sequence-specific manner, directly from bodily fluid samples without the need for complex sample preparation.
  • Preferred embodiments include obtaining a bodily fluid sample from a subject.
  • Certain embodiments of the invention provide a method for detecting a target nucleic acid in the bodily fluid sample.
  • Certain other embodiments of the invention also provide for the detection of methylation in DNA, in a sequence-specific manner, directly from biological samples without the need for complex sample preparation or sequencing.
  • the sample is positively enriched for the target region and methylation is detected.
  • the target region is suspected to be hypermethylated.
  • Methods of the invention include introducing the Cas endonuclease, catalytically inactive Cas endonuclease, or homolog thereof and guide RNA into the bodily fluid sample.
  • the binding proteins are provided by Cas endonuclease/guide RNA complexes.
  • Embodiments of the invention use Cas endonuclease proteins that are originally encoded by genes that are associated with clustered regularly interspaced short palindromic repeats (CRISPR) in bacterial genomes.
  • CRISPR-associated (Cas) endonuclease may be introduced directly into the bodily fluid sample.
  • the Cas proteins bind to ends of a target nucleic acid.
  • the target nucleic acid is thus isolated or enriched in a sequence-specific manner.
  • the enriched target nucleic acid may then be subject to any suitable detection or analysis assay such as amplification or sequencing.
  • the enriched target nucleic acid may be further enriched by digesting other, unbound nucleic acids present in the sample with exonuclease.
  • the bound Cas proteins prevent the exonuclease from digesting the target nucleic acid, thereby leaving the only the target nucleic acid substantially present in the sample.
  • the target nucleic acid is thus isolated or enriched in a sequence-specific manner.
  • the target nucleic acid may then be subject to any suitable detection or analysis assay such as amplification or sequencing.
  • the target may be subjected to a signal amplification assay, for example, an immunoassay.
  • the Cas endonuclease is complexed with a guide RNA that targets the Cas endonuclease to a specific sequence.
  • the Cas endonuclease/guide RNA complex targets and binds to one or more target regions of DNA suspected to be hypermethylated. Any suitable Cas endonuclease or homolog thereof may be used.
  • a Cas endonuclease may be Cas9 (e.g., spCas9), catalytically inactive Cas (dCas such as dCas9), Cpfl (aka Casl2a), C2c2, Casl3, Casl3a, Casl3b, e.g., PsmCasl3b, LbaCasl3a, LwaCasl3a, AsCasl2a, others, modified variants thereof, and similar proteins or macromolecular complexes.
  • the Cas 13 proteins may be preferred where the target includes RNA.
  • a Cas endonuclease/guide RNA complex includes a first Cas endonuclease and a first guide RNA.
  • the complex comprises the Cas endonuclease or the catalytically deficient homolog thereof being introduced into the serum or plasma as a ribonucleoprotein (RNP) in which the Cas endonuclease or catalytically deficient homolog thereof is complexed with the guide RNA.
  • RNP ribonucleoprotein
  • the Cas endonuclease will bind to the target.
  • the target may then be isolated or enriched, allowing for detection of the target.
  • the proteins that bind to ends of the target nucleic acid may be any proteins that bind to a nucleic acid in a sequence-specific manner.
  • the protein may be a programmable nuclease.
  • the protein may be a CRISPR-associated (Cas) endonuclease, zinc-finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or RNA-guided engineered nuclease (RGEN).
  • Cas CRISPR-associated
  • ZFN zinc-finger nuclease
  • TALEN transcription activator-like effector nuclease
  • RGEN RNA-guided engineered nuclease Programmable nucleases and their uses are described in, for example, Zhang, 2014, "CRISPR/Cas9 for genome editing: progress, implications and challenges", Hum Mol Genet 23 (Rl):R40-6; Ledford, 2016.
  • CRISPR gene editing is just the beginning, Nature. 531 (7593): 156-9; Hsu, 2014, Development and applications of CRISPR-Cas9 for genome engineering, Cell 157(6): 1262-78; Boch, 2011, TALEs of genome targeting, Nat Biotech 29(2): 135-6; Wood, 2011, Targeted genome editing across species using ZFNs and TALENs, Science 333(6040):307; Carroll, 2011, Genome engineering with zinc-finger nucleases, Genetics Soc Amer l88(4):773-782; and Umov, 2010, Genome Editing with Engineered Zinc Finger Nucleases, Nat Rev Genet l l(9):636-646, each incorporated by reference.
  • the protein may be a catalytically inactive form of a nuclease, such as a programmable nuclease described above.
  • the protein may be a transcription activator- like effector (TALE).
  • TALE transcription activator- like effector
  • the protein may be complexed with a nucleic acid that guides the protein to an end of the target nucleic acid.
  • the protein may be a Cas endonuclease in a complex with one or more guide RNAs.
  • the protein is a Cas endonuclease, catalytically inactive Cas endonuclease, or homologs thereof.
  • the sample includes cfDNA from a subject.
  • the sample is exposed to a first Cas endonuclease/guide RNA complex that binds to a target nucleic acid (e.g., a mutation of interest) in a sequence- specific fashion.
  • the complex binds to a mutation in a sequence- specific manner.
  • a segment of the nucleic acid, i.e., the target nucleic acid is protected by introducing the first Cas endonuclease/guide RNA complex and a second Cas endonuclease/guide RNA complex that also binds to the nucleic acid.
  • the guide RNA comprises at least two guide RNA molecules that each complex with a Cas endonuclease and guide the Cas endonuclease to hybridize to one target nucleic acid, wherein the target nucleic acid includes a loci know to harbor a cancer-associated mutation.
  • the sample includes cfDNA from a subject.
  • the sample is exposed to a first Cas endonuclease/guide RNA complex that binds to a target region of DNA (e.g., a region suspected to be hypermethylated) in a sequence-specific fashion.
  • the complex targets and binds to a one or more PAM sequences in a sequence specific manner that are adjacent the target region suspected to be hypermethylated.
  • a segment of the DNA, i.e., the target region is protected by introducing the first Cas endonuclease/guide RNA complex and a second Cas endonuclease/guide RNA complex that also binds to the DNA.
  • the guide RNA comprises at least two guide RNA molecules that each complex with a Cas endonuclease and guide the Cas endonuclease to hybridize to a target region of DNA, wherein the target region includes a loci know to be hypermethylated .
  • unprotected nucleic acid is digested.
  • one or more exonucleases may be introduced that promiscuously digest unbound, unprotected nucleic acid.
  • Any suitable exonuclease may be used.
  • Suitable exonucleases include, for example, Lambda exonuclease, RecJf, Exonuclease III, Exonuclease I, Exonuclease T, Exonuclease V, Exonuclease VII, T5 Exonuclease, and T7 Exonuclease, most of which are available from New England Biolabs (Ipswich, MA). While the exonucleases act, the target nucleic acid is protected by the bound complexes and survives the digestion step intact.
  • the described steps including the digestion by the exonuclease leave a reaction product that includes principally only the mutant segment of nucleic acid, as well as any spent reagents, Cas endonuclease complexes, exonuclease, nucleotide monophosphates, and pyrophosphate as may be present.
  • the exonuclease is deactivated.
  • exonuclease may be deactivated by following the manufacturer’s instructions e.g., by heating to 90 degrees for a few minutes.
  • a positive selection step may be performed which may include, for example, amplification of the target nucleic acid by known methods or selection by an affinity assays.
  • the nucleic acid may be any naturally-occurring or artificial nucleic acid.
  • the nucleic acid may be DNA, RNA, hybrid DNA/RNA, peptide nucleic acid (PNA), morpholino and locked nucleic acid (LNA), glycol nucleic acid (GNA), threose nucleic acid (TNA), or Xeno nucleic acid.
  • the RNA may be a subpopulation of RNA, such as mRNA, tRNA, rRNA, miRNA, or siRNA.
  • the nucleic acid is DNA.
  • the target or feature of interest may be any feature of a nucleic acid.
  • the feature may be a mutation.
  • the feature may be an insertion, deletion, substitution, inversion, amplification, duplication, translocation, or polymorphism.
  • the feature may be a nucleic acid from an infectious agent or pathogen.
  • the nucleic acid sample may be obtained from an organism, and the feature may contain a sequence foreign to the genome of that organism.
  • the target region or feature of interest may be any site of epigenetic modification that is indicative of a disease, such as a nucleic acid modification, a histone modification, or chromatin remodeling.
  • An example of a nucleic acid modification may be a modification to methylation status of DNA.
  • a feature of interest may be DNA hypermethylation or hypomethylation.
  • the methods of the invention involve the detection of DNA hypermethylation.
  • Histone modifications can also constitute an epigenetic modification indicative of disease. Examples of histone modifications include but are not limited to methylation, acetylation, deacetylation, ADP-ribosylation, ubiquitination or phosphorylation.
  • Other examples of epigenetic elements indicative of disease include RNA interference (e.g., short interfering RNA, also known as siRNA) and prions.
  • the target nucleic acid may be from a sub-population of nucleic acid within the nucleic acid sample.
  • the target nucleic acid may contain cell-free DNA, such as cell-free fetal DNA or circulating tumor DNA.
  • the sample includes plasma from the subject and the target nucleic acid is cell-free DNA (cfDNA).
  • the plasma may be maternal plasma and the target may be of fetal DNA.
  • the sample includes plasma from the subject and the target is circulating tumor DNA (ctDNA).
  • the sample includes at least one circulating tumor cell from a tumor and the target is tumor DNA from the tumor cell.
  • the target nucleic acid is complementary DNA (cDNA), which is made by reverse transcribing RNA.
  • detecting cDNA is a way to detecting target RNA.
  • the target nucleic acid may be from any source of nucleic acid.
  • the target nucleic acid may be from any source of nucleic acid.
  • the target nucleic acid is from a bodily fluid sample from a human.
  • the bodily fluid sample is a liquid or bodily fluid from a subject, such as bile, blood, plasma, serum, sweat, saliva, urine, feces, phlegm, mucus, sputum, tears, cerebrospinal fluid, synovial fluid, pericardial fluid, lymphatic fluid, semen, vaginal secretion, products of lactation or menstruation, amniotic fluid, pleural fluid, rheum, vomit, or the like.
  • the bodily fluid sample is a blood sample, serum sample, plasma sample, urine sample, saliva sample, semen sample, feces sample, phlegm sample, or liquid biopsy.
  • the sample may be a tissue sample from an animal, such as skin, conjunctiva, gastrointestinal tract, respiratory tract, vagina, placenta, uterus, oral cavity or nasal cavity.
  • the sample may be a liquid biopsy or a tissue biopsy.
  • the method optionally includes detecting the target nucleic acid (which may harbor the mutation). Any suitable technique may be used to detect the target nucleic acid. For example, detection may be performed using DNA staining, spectrophotometry, sequencing, fluorescent probe hybridization, fluorescence resonance energy transfer, optical microscopy, electron microscopy, others, or combinations thereof. Detecting the target nucleic acid may indicate the presence of the mutation in the subject (i.e., a patient), and a report may be provided describing the mutation in the patient.
  • detecting methylation in DNA of the target region is performed. Any suitable technique may be used to detect methylation in the target region of DNA. For example, detection may be performed using known hybridization assays, such as those that utilize antibodies, or other signal amplification techniques, such as an immunoassay, like an ELISA. The described methodology may be used to detect hypermethylation in the target region. In such cases, site-specific hypermethylation detection may be used to detect the presence of cancer.
  • a sample may contain a mutant fragment of DNA, a wild-type fragment of DNA, or both.
  • a locus of interest is identified where a mutation may be present proximal to, or within, a protospacer adjacent motif (PAM).
  • PAM protospacer adjacent motif
  • the wild-type fragment When the wild-type fragment is present, it may contain a wild-type allele at a homologous location in the fragment, also proximal to, or within, a PAM.
  • a guide RNA is introduced to the sample that has a targeting portion complementary to the portion of the mutant fragment that includes the mutation. When a Cas endonuclease is introduced, it will form a complex with the guide RNA and bind to the mutant fragment but not to the wild-type fragment.
  • the first Cas endonuclease/guide RNA complex includes a guide RNA with a targeting region that binds to the mutation but that does not bind to other variants at a loci of the mutation.
  • the described methodology may be used to target a mutation that is proximal to a PAM, or it may be used to target and detect a mutation in a PAM, e.g., a loss-of-PAM or gain-of-PAM mutation.
  • the described methodology may be used to target a mutation that is proximal to a PAM, or it may be used to target and detect a mutation in a PAM, e.g., a loss-of-PAM or gain-of-PAM mutation.
  • the PAM is typically specific to, or defined by, the Cas endonuclease being used.
  • the PAM includes NGG, and the targeted portion includes the 20 bases immediately 5’ to the PAM.
  • the targetable portion of the DNA includes any twenty-three consecutive bases that terminate in GG or that are mutated to terminate in GG.
  • Such a pattern may be found to be distributed over ctDNA at such frequency that the potentially detectable mutations are abundant enough as to be representative of mutations over the tumor DNA at large.
  • mutation- specific enrichment may be used to detect mutations from a tumor.
  • methods may be used to determine a number of mutations over the representative, targetable portion of tumor DNA. Since the targetable portion of the genome is representative of the tumor DNA overall, the number of mutations may be used to infer a mutational burden for the tumor.
  • a sample may contain a mutant fragment of DNA, a wild-type fragment of DNA, or both.
  • a locus of interest is identified where
  • hypermethylation may be present adjacent to a protospacer adjacent motif (PAM).
  • a guide RNA is introduced to the sample that has a targeting portion complementary to PAM sequences that are adjacent a target region suspected to be hypermethylated.
  • a Cas endonuclease When a Cas endonuclease is introduced, it will form a complex with the guide RNA and the complex will target and bind to the PAM sequences.
  • the Cas endonuclease/guide RNA complex includes a guide RNA with a targeting region that binds to the PAM but that does not bind to other regions at a loci of the target region.
  • the described methodology may be used to target and detect DNA methylation adjacent to a PAM.
  • the described methodology may be used to target DNA methylation adjacent to a PAM, or it may be used to target a region and detect DNA hypermethylation adjacent a PAM.
  • the targetable portion of the DNA includes any twenty-three consecutive bases that terminate in GG.
  • enrichment may be used to detect methylated target regions of DNA known to be associated with cancer.
  • methods may be used to quantify DNA methylation levels of the target region of DNA. Since the targetable portion of the genome is representative of the tumor DNA overall, the hypermethylation levels may be used to infer a mutational burden for the tumor.
  • a feature of the method is that a specific mutation may be detected by a technique that includes detecting only the presence or absence of a fragment of DNA, and it need not be necessary to sequence DNA from a subject to describe mutations.
  • Methods of the invention use protection at one or both ends of DNA segments.
  • the gRNA selects for a known mutation on one end. A positive selection may be performed to positively select out the bound, target nucleic acid. If the gRNA does not find the mutation, no protection is provided and the molecule may be digested, e.g. in negative enrichment, and the remaining molecules are either counted or sequenced.
  • Methods are well suited for the analysis of samples in which the target of interest is extremely rare, and particularly for the analysis of maternal plasma or serum (e.g., for fetal DNA) or a liquid biopsy (e.g., for ctDNA). Such methods of the invention are useful for detection of hypermethylation of target region of DNA known to be associated with cancer.
  • the Cas endonuclease/gRNA complex targets and binds to PAM adjacent to the target region suspected to be hypermethylated.
  • Methods are useful for the isolation of intact DNA fragments of any arbitrary length and may preferably be used in some embodiments to isolate (or enrich for) arbitrarily long fragments of DNA, e.g., tens, hundreds, thousands, or tens of thousands of bases in length or longer.
  • Long, isolated, intact fragments of DNA may be analyzed by any suitable method such as simple detection (e.g., via staining with ethidium bromide) or by single-molecule sequencing. It is noted that the Cas9/gRNA complexes may be subsequently or previously labeled using standard procedures.
  • the complexes may be fluorescently labeled, e.g., with distinct fluorescent labels such that detecting involves detecting both labels together (e.g., after a dilution into fluid partitions).
  • Preferred embodiments of the detection do not require PCR amplification and therefore significantly reduces cost and sequence bias associated with PCR amplification.
  • Sample analysis can also be performed by a number of approaches, such as next generation sequencing (NGS), etc.
  • NGS next generation sequencing
  • many analytical platforms may require PCR amplification prior to analysis. Therefore, preferred embodiments of analysis of the reaction products include single molecule analysis that avoids the requirement of amplification.
  • Kits and methods of the invention are useful with methods disclosed in U.S. Provisional Patent Application 62/526,091, filed June 28, 2017, for POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES and U.S. Provisional Patent Application 62/519,051, filed June 13, 2017, for POLYNUCLEIC ACID MOLECULE ENRICHMENT METHODOLOGIES, both incorporated by reference.
  • the target nucleic acid may be detected, sequenced, or counted. Where a plurality of fragments are present or expected, the fragment may be quantified, e.g., by qPCR.
  • the target nucleic acid may further be isolated or detected by any suitable method in order to separate the target segment from other nucleic acids in the sample.
  • the isolation or detection method may include separating the protein-bound target nucleic acid from some or all of the unbound nucleic acid.
  • the isolation or detection method may include binding the protein-bound target nucleic acid to a particle.
  • the particle may include magnetic or paramagnetic material.
  • the isolation or detection method may include applying a magnetic field to the sample.
  • the particle may include an agent that binds to a protein bound to an end of the target nucleic acid.
  • the agent may an antibody or fragment thereof.
  • the isolation or detection method may include chromatography.
  • the isolation or detection method may include applying the sample to a column.
  • the isolation or detection method may include separating the protein- bound target nucleic acid from some or all of the unbound nucleic acid by size exclusion, ion exchange, or adsorption.
  • the isolation or detection method may include gel electrophoresis
  • the target DNA may further be enriched or isolated by any suitable method in order to separate the target segment from other components in the sample.
  • the isolation or detection method may include separating the complex -bound target region DNA from some or all of the unbound DNA.
  • the isolation method may include binding the complex -bound target region to a particle.
  • the particle may include magnetic or
  • the isolation or detection method may include applying a magnetic field to the sample.
  • the particle may include an agent that binds to a protein bound to an end of the target DNA.
  • the agent may an antibody or fragment thereof.
  • the isolation or detection method may include chromatography.
  • the isolation or detection method may include applying the sample to a column.
  • the isolation or detection method may include separating the complex- bound target DNA from some or all of the unbound DNA by size exclusion, ion exchange, or adsorption.
  • the enrichment or isolation method may include gel electrophoresis.
  • Embodiments of the invention may include detecting the target nucleic acid and optionally providing a report describing a mutation as present in the patient. In some
  • the target nucleic acid is a target region of DNA suspected to be hypermethylated.
  • the mutation-containing fragments may be detected by a suitable assay, such as sequencing, gel electrophoresis, a probe-based assay.
  • the detection of the isolated segment of the target nucleic acid may be done by sequencing.
  • the detection of the methylation of the isolated target r may be done by any known signal amplification technique in the art.
  • the digestion or the isolation provides a reaction product that includes principally only the target nucleic acid, as well as any spent reagents, Cas endonuclease complexes, exonuclease (e.g. when negative enrichment is performed), nucleotide monophosphates, or pyrophosphate as may be present.
  • the reaction product may be provided as an aliquot (e.g., in a micro centrifuge tube such as that sold under the trademark EPPENDORF by Eppendorf North America (Hauppauge, NY) or glass cuvette).
  • the reaction product aliquot may be disposed on a substrate.
  • the reaction product may be pipetted onto a glass slide and subsequently combed or dried to extend the fragment across the glass slide.
  • the reaction product may optionally be amplified.
  • adaptors are ligated to ends of the reaction product, which adaptors may contain primer sites or sequencing adaptors. The presence of the segment in the reaction product aliquot may then be detected using an instrument.
  • the target nucleic acid may be detected by any means known in the art.
  • the target nucleic acid may be detected by DNA staining, spectrophotometry, sequencing, fluorescent probe hybridization, fluorescence resonance energy transfer, optical microscopy, or electron microscopy.
  • Detecting the nucleic acid may include identifying a mutation in the nucleic acid.
  • detecting the nucleic acid may include detecting methylation at the Identifying the mutation may include sequencing the nucleic acid (e.g., on a next-generation sequencing instrument), allele- specific amplification, and hybridizing a probe to the nucleic acid.
  • One method for detection of protein-bound nucleic acids is immunomagnetic separation. Magnetic or paramagnetic particles are coated with an antibody that binds the protein bound to the segment, and a magnetic field is applied to separate particle-bound segment from other nucleic acids.
  • Methods of immunomagnetic purification of biological materials such as cells and macromolecules are known in the art and described in, for example, U.S. Patent No. 8,318,445; Safarik and Safarikova, Magnetic techniques for the isolation and purification of proteins and peptides, Biomagn Res Technol. 2004; 2:7, doi: 10.1186/1477-044X-2-7, the contents of each of which are incorporated herein by reference.
  • the antibody may be a full-length antibody, a fragment of an antibody, a naturally occurring antibody, a synthetic antibody, an engineered antibody, or a fragment of the aforementioned antibodies.
  • the particles may be coated with another protein-binding moiety, such as an aptamer, peptide, receptor, ligand, or the like.
  • the particles are coated with biotin-binding protein, such as Streptavidin.
  • the magnetic separation of the complex-bound regions provides for enrichment and isolation of the target region.
  • the target region may be suspected to be hypermethylated.
  • Chromatographic methods may be used for detection.
  • the bodily fluid sample is applied to a column, and the target nucleic acid is separated from other nucleic acids based on a difference in the properties of the target nucleic acid and the other nucleic acids.
  • Size exclusion chromatography is useful for separating molecules based on differences in size and thus is useful when the segment is larger than other nucleic acids, for example the residual nucleic acids left from a digestion step.
  • Methods of size exclusion chromatography are known in the art and described in, for example, Ballou, David P.; Benore, Marilee; Ninfa, Alexander J. (2008). Fundamental laboratory approaches for biochemistry and biotechnology (2nd ed.). Hoboken, N.J.: Wiley p. 129.
  • Ion exchange chromatography uses an ion exchange mechanism to separate analytes based on their respective charges.
  • ion exchange chromatography can be used with the proteins bound to the target nucleic acid impart a differential charge as compared to other nucleic acids.
  • Methods of ion exchange chromatography are known in the art and described in, for example, Small, Hamish (1989). Ion chromatography. New York: Plenum Press. ISBN 0-306- 43290-0; Tatjana Weiss, and Joachim Weiss (2005). Handbook of Ion Chromatography.
  • Adsorption chromatography relies on difference in the ability of molecule to adsorb to a solid phase material. Farger nucleic acid molecules are more adsorbent on stationary phase surfaces than smaller nucleic acid molecules, so adsorption chromatography is useful when the target nucleic acid is larger than other nucleic acids, for example the residual nucleic acids left from a digestion step. Methods of adsorption chromatography are known in the art and described in, for example, Cady, 2003, Nucleic acid purification using microfabricated silicon structures.
  • Biosensors and Bioelectronics 19:59-66; Melzak, 1996, Driving Forces for DNA Adsorption to Silica in Perchlorate Solutions, J Colloid Interface Sci 181:635-644; Tian, 2000, Evaluation of Silica Resins for Direct and Efficient Extraction of DNA from Complex Biological Matrices in a Miniaturized Format, Anal Biochem 283:175-191; and Wolfe, 2002, Toward a microchip-based solid-phase extraction method for isolation of nucleic acids, Electrophoresis 23:727-733, each incorporated by reference.
  • Gel electrophoresis allows separation of molecules based on differences in their sizes and is thus useful when the target nucleic acid is larger than other nucleic acids, for example the residual nucleic acids left from a digestion step.
  • Methods of gel electrophoresis are known in the art and described in, for example, Tom Maniatis; E. F. Fritsch; Joseph Sambrook. "Chapter 5, protocol 1". Molecular Cloning - A Laboratory Manual. 1 (3rd ed.). p. 5.2-5.3. ISBN 978-0879691363; and Ninfa, Alexander J.; Ballou, David P.; Benore, Marilee (2009). fundamental laboratory approaches for biochemistry and biotechnology. Hoboken, NJ: Wiley p. 161. ISBN 0470087668, the contents of which are incorporated herein by reference.
  • Methods of the invention involve signal amplification techniques, such as antibody-based detection and analysis.
  • signal amplification techniques such as antibody-based detection and analysis.
  • antibody-based detection methods are generally based on the transformation of a specific biomolecular interaction between antigen and antibody into a macroscopically detectable signal or change in the physical properties of the media. See e.g., Sveshnikov, Peter;“The Potential of Different Biotechnology Methods in BTW Agent Detection: Antibody Based Methods” The Role of Biotechnology in Countering BTW Agents; Vol. 34 of the series NATO Science Series, pp. 69-77 (2001), incorporated herein by reference.
  • Proteins can be detected and quantified through epitopes recognized by polyclonal and/or monoclonal antibodies used in methods such as enzyme-linked immunoabsorbent assay (ELISA), immunoblot assays, flow cytometric assays, radioimmuno assays, immunocytochemical assays, Western blot assays, an immunofluorescent assays, chemiluminescent assays, flow cytometry and fluorescence-activated cell sorting (FACS), immunoprecipitation, enzyme linked immunospot (ELISPOT), and other polypeptide detection strategies. Proteins may also be detected by mass spectrometry assays (potentially coupled to immunoaffinity assays) including matrix-assisted laser
  • MALDI-TOF desorption/ionization time-of-flight
  • methods of the disclosed invention may include tagging of proteins separated by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), (Kiernan et al, Anal Biochem 301, 49-56 (2002); Poutanen et al, Mass Spectrom 15, 1685-1692 (2001) the content of each of which is incorporated by reference herein in its entirety) or any other method of detecting protein.
  • 2D-PAGE two-dimensional polyacrylamide gel electrophoresis
  • hypermethylation of a target region In these methods, antibodies (monoclonal or polyclonal) specific for each target region are used to detect hypermethylation. Immunohistochemistry protocols and kits are well known in the art and are commercially available.
  • Certain preferred embodiments include obtaining a blood, plasma, or serum sample from a patient.
  • the blood, plasma, or serum may include cfDNA and thus also include ctDNA among the cfDNA.
  • Specific sequences of the ctDNA are isolated or enriched and analyzed or detected to detect or report genetic information from the subject, such as a presence or count of certain tumor mutations.
  • Methods of the invention include introduce Cas endonucleases (or catalytically inactive homologs thereof such as dCas9) directly into serum or plasma.
  • the Cas endonucleases are complexed with guide RNAs that include targeting portions specific for a target nucleic acid. In the plasma or serum, the complexes bind to ends of the target and protect it.
  • Exonuclease may be introduced to digest unbound nucleic acid into monomers and fragments too small for further meaningful detection, sequencing, or amplification.
  • a blood sample may be obtained from a patient.
  • the sample may be collected in any suitable blood collection tube such as the collection tube sold under the trademark VACETTAINER by BD (Franklin Lakes, NJ).
  • the collection tube comprises an EDTA collection tube, and Na-EDTA collection tube or the collection tube sold under the trademark CELL-FREE DNA BCT by Streck, Inc. (La Vista, NE), sometimes referred to in the art as a Streck tube.
  • Streck tube Use of a Streck tube stabilizes nucleated blood cells and prevents the release of genomic DNA into the sample. This facilitates the collection of sample that includes cell-free DNA.
  • the sample may be centrifuged to generate a sample that includes a pellet of blood cells and a supernatant, which contains serum or plasma.
  • Serum is the liquid supernatant of whole blood that is collected after the blood is allowed to clot and centrifuged.
  • Plasma is produced when the process includes an anticoagulant.
  • To collect serum blood is collected in tubes. After collection, the blood is allowed to clot by leaving it undisturbed at room temperature (about 15- 30 minutes). The clot is removed by centrifuging, e.g., at 1,000-2,000 x g for 10 minutes in a refrigerated centrifuge. The resulting supernatant is designated serum and may be transferred to a clean polypropylene tube using a Pasteur pipette.
  • blood is collected into
  • the sample includes plasma or serum, which includes cfDNA.
  • serum or plasma is transferred from a centrifuge tube to a new tube, complexes comprising Cas9 and guide RNA are added, and the mixture is incubated.
  • amplification or an affinity assay may be performed to positively select out the bound, target nucleic acid.
  • exonuclease may be introduced to digest unbound, non-target DNA, and then the exonuclease may be deactivated (e.g., by heat).
  • a positive selection may then follow (e.g., amplification or an affinity assay) to positively select out the bound, target nucleic acid.
  • plasma or serum is removed from the centrifuge tube (the supernatant) and transferred into a new tube.
  • Appropriate buffers/reagents are added to modify a chemical environment to promote binding of Cas endonuclease to the target nucleic acid. For example, pH can be adjusted, as may temperature, salinity, or co-factors present.
  • the Cas complexes are added and allowed to incubate. For example, amplification or an affinity may be performed to positively select out the bound, target nucleic acid.
  • An exonuclease may optionally be added, which ablates all free, non-target nucleic acid.
  • the target may be positively selected such as by amplification or an affinity assay after exonuclease digestion of the non target nucleic acid.
  • Methods may include detection or isolation of circulating tumor cells (CTCs) from a blood sample.
  • CTCs circulating tumor cells
  • Cytometric approaches use immuno staining profiles to identify CTCs.
  • CTC methods may employ an enrichment step to optimize the probability of rare cell detection, achievable through immune-magnetic separation, centrifugation, or filtration.
  • Cytometric CTC technology includes the CTC analysis platform sold under the trademark CELLSEARCH by Veridex LLC (Huntingdon Valley, PA). Such systems provide semi-automation and proven reproducibility, reliability, sensitivity, linearity and accuracy.
  • kits may provide a kit.
  • the kit preferably includes reagents and materials useful for performing methods of the invention.
  • the kit may include one or more guide RNA that, taken in pairs, are designed to flank cancer-associated mutations.
  • the kit may include one or more guide RNAs that are mutation specific and only hybridize to target that includes a mutation.
  • the kit may include a Cas endonuclease or a nucleic acid encoding a Cas endonuclease such as a plasmid.
  • the kit may optionally include
  • the kit may include reagents for adjusting conditions such as pH, salinity, co factors, etc., to promote binding or activity of Cas endonuclease (including to promote binding of catalytically inactive Cas endonuclease, which may be included as the Cas endonuclease) in the bodily fluid sample, such as plasma or serum.
  • the kit may further include instructional materials for performing methods of the invention, and components of the kit may be packaged in a box suitable for shipping or storage.
  • the kit contains one or more collection tubes, such as a blood collection tube.
  • the kit may include one or more guide RNA that, taken in pairs, are designed to flank cancer-associated methylation sites.
  • the kit may include one or more guide RNAs that are target specific and only hybridize to PAM sequences adjacent to the target region that includes a methylation site suspected to be hypermethylated.
  • the Cas endonuclease/guide RNA complexes can be designed to bind to mutations of clinical significance, such as a mutation specific to a tumor.
  • the complexes can be designed to target and bind to one or more target regions of DNA suspected to be hypermethylated, where such hypermethylation is specific to a tumor.
  • a report may be provided to, for example, describe the mutation in a patient or a subject.
  • certain embodiments may comprise providing a report.
  • the report preferably includes a description of the mutation in the subject (e.g., a patient).
  • the method for detecting rare nucleic acid may be used in conjunction with a method of describing mutations (e.g., as described herein).
  • Either or both detection processes may be performed over any number of loci in a patient’s genome or preferably in a patient’s tumor DNA.
  • the report may include a description of a plurality of structural alterations, mutations, or both in the patient’s genome or tumor DNA.
  • the report may give a description of a mutational landscape of a tumor.
  • the report may provide a description of the DNA methylation in the target region of the subject.
  • Knowledge of a mutational landscape of a tumor may be used to inform treatment decisions, monitor therapy, detect remissions, or combinations thereof.
  • the report may also include an estimate of a tumor mutation burden (TMB) for a tumor.
  • TMB tumor mutation burden
  • TMB is predictive of success of immunotherapy in treating a tumor, and thus methods described herein may be used for treating a tumor.
  • knowledge of DNA methylation of a target region may also be used similarly.
  • Methods of the invention thus may be used to detect and report clinically actionable information about a patient or a tumor in a patient.
  • the method may be used to provide a report describing the presence of the genomic alteration in a genome of a subject.
  • the method may be used to provide a report describing the DNA methylation of a target region known to be associated with cancer of a subject.
  • protecting a segment of DNA, and optionally digesting unprotected DNA provides a method for isolation or enrichment of DNA fragments, i.e., the protected segment. It may be found that the described enrichment techniques are well-suited to the isolation/enrichment of arbitrarily long DNA fragments, e.g., thousands to tens of thousands of bases in length or longer.
  • Negative enrichment may be used to enrich“representative” genomic regions that can allow an investigator to identify“off rate” when performing CRISPR Cas9 experimentation, as well as enrich for genomic regions that would be used to determine TMB for immuno-oncology associated therapeutic treatments.
  • the negative enrichment technology is utilized to enrich large regions (> 50 kb) within the genome of interest.
  • the methods described herein provide the ability to assay for methylation and other epigenetic changes that are indicative of disease.
  • Methods of the invention are conducive to high-throughput testing, and may be performed, for example, in droplets on a microfluidic device, to rapidly assay a large number of aliquots from a sample for one or any number of genomic structural alterations.
  • a biological sample can be assayed for hypermethylation or other epigenetic changes in target regions using a technique that does not require bisulfite treatment of DNA to detect methylation.
  • Plasma samples were placed in Streck tubes and in standard tubes. The experiments used an 800 bp amplicon from the cystic fibrosis transmembrane receptor gene. Dilutions were made of CFTR F2 800 bp into plasma with 5 million copies per reaction total ( Figure 1). The percent plasma in reaction after dilution was 50%, 25%, 16.7%, 10%, 2%, 1%, 0.5%, 0.2%, 0.1%, and 0% ( Figure 2).
  • the results also indicated a relationship between the qPCR signal and percent plasma (Figure 6).
  • the data show Cas9 exhibits detectable cutting in Na-EDTA plasma.
  • cutting efficiency in 2% plasma or lower resembled no plasma cutting efficiency (82.82% for in plasma compared to 79.97% in no plasma).
  • the cutting efficiency in 25% plasma or lower resembled no-plasma cutting efficiency (83.14% compared to 78.90%).
  • CRISPR/Cas9 complexes retained 75% activity. Results of the data show that Cas endonuclease and homologs thereof bind to target DNA under guidance of guide RNA in plasma.
  • sequence specific Cas9/gRNA complexes were added directly to a biological sample, a plasma sample.
  • a complex of Cas9-guide RNA and a particle, in this example, a magnetic bead coated with streptavidin is directly inserted into the plasma sample. That is, the magnetic bead bound Cas proteins bind to expected targets under guide RNA guidance in plasma (or serum) and cut and protect the target region to achieve enrichment.
  • the target region is suspected to be hypermethylated and the complexes were complementary to both sides the target region of DNA. The complexes therefore targeted and bound to PAM sequences that were adjacent to the target region suspected to be

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés permettant de détecter des changements épigénétiques, comprenant, mais sans s'y limiter, des changements de méthylation, directement à partir d'échantillons biologiques, sans avoir besoin de certaines étapes de préparation d'échantillon complexes. L'invention concerne des complexes de protéine Cas/ARN de guidage qui peuvent être introduits directement dans l'échantillon, où les complexes ciblent et se lient à la région cible. La région cible est ainsi enrichie et isolée d'une manière spécifique de séquence. La région cible peut ensuite être soumise à n'importe quel essai approprié d'amplification de signal pour détecter le changement épigénétique dans la région cible. La détection d'une hyperméthylation de l'ADN dans la région cible indique une maladie, telle qu'un cancer.
PCT/US2018/054188 2018-05-16 2018-10-03 Enrichissement et détection de méthylation spécifique à une séquence WO2019221769A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3100492A CA3100492A1 (fr) 2018-05-16 2018-10-03 Enrichissement et detection de methylation specifique a une sequence
EP18919343.6A EP3794139A4 (fr) 2018-05-16 2018-10-03 Enrichissement et détection de méthylation spécifique à une séquence

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862672217P 2018-05-16 2018-05-16
US62/672,217 2018-05-16
US16/018,926 2018-06-26
US16/018,926 US20190002964A1 (en) 2017-06-28 2018-06-26 Bodily fluid target enrichment

Publications (1)

Publication Number Publication Date
WO2019221769A1 true WO2019221769A1 (fr) 2019-11-21

Family

ID=68540705

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2018/054188 WO2019221769A1 (fr) 2018-05-16 2018-10-03 Enrichissement et détection de méthylation spécifique à une séquence
PCT/US2018/055648 WO2019221773A1 (fr) 2018-05-16 2018-10-12 Détection et surveillance de tumeur

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2018/055648 WO2019221773A1 (fr) 2018-05-16 2018-10-12 Détection et surveillance de tumeur

Country Status (3)

Country Link
EP (2) EP3794139A4 (fr)
CA (2) CA3100492A1 (fr)
WO (2) WO2019221769A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006908A1 (fr) * 2022-06-30 2024-01-04 Guardant Health, Inc. Enrichissement d'adn méthylé de manière aberrante

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081829B1 (en) 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions
US20210155972A1 (en) * 2019-11-27 2021-05-27 Genetics Research, Llc Targeted rare allele crispr enrichment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160017396A1 (en) * 2014-07-21 2016-01-21 Illumina, Inc. Polynucleotide enrichment using crispr-cas systems
US20170014449A1 (en) * 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109256B2 (en) * 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
US8916530B2 (en) * 2005-11-18 2014-12-23 Gradalis, Inc. Individualized cancer therapy
WO2016028887A1 (fr) * 2014-08-19 2016-02-25 Pacific Biosciences Of California, Inc. Compositions et méthodes pour l'enrichissement d'acides nucléiques
WO2016186946A1 (fr) * 2015-05-15 2016-11-24 Pioneer Hi-Bred International, Inc. Caractérisation rapide de systèmes d'endonucléases cas, séquences pam et éléments d'arn guide
US10081829B1 (en) * 2017-06-13 2018-09-25 Genetics Research, Llc Detection of targeted sequence regions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160017396A1 (en) * 2014-07-21 2016-01-21 Illumina, Inc. Polynucleotide enrichment using crispr-cas systems
US20170014449A1 (en) * 2015-07-13 2017-01-19 Elwha LLC, a limited liability company of the State of Delaware Site-specific epigenetic editing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KURDYKOV, S ET AL.: "DNA Methylation Analysis: Choosing the Right Method", BIOLOGY, vol. 5, no. 1, 6 January 2016 (2016-01-06), pages 1 - 21, XP055468691, DOI: 10.3390/biology5010003 *
See also references of EP3794139A4 *
STUNKEL, W ET AL.: "Programming the Transcriptional State of Replicating Methylated DNA", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 23, 6 March 2001 (2001-03-06), pages 20743 - 20749, XP055656091 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006908A1 (fr) * 2022-06-30 2024-01-04 Guardant Health, Inc. Enrichissement d'adn méthylé de manière aberrante

Also Published As

Publication number Publication date
WO2019221773A1 (fr) 2019-11-21
EP3794139A1 (fr) 2021-03-24
CA3100492A1 (fr) 2019-11-21
EP3655546A1 (fr) 2020-05-27
EP3655546A4 (fr) 2021-04-07
CA3069939A1 (fr) 2019-11-21
EP3794139A4 (fr) 2022-06-01

Similar Documents

Publication Publication Date Title
EP2505666B1 (fr) Procédés et compositions pour l'enrichissement soit de polynucléotides cibles ou de polynucléotides non-cibles à partir d'un mélange de polynucléotides cibles et non-cibles
EP1169479B1 (fr) Procedes de detection d'acides nucleiques revelateurs de cancer
US20190048425A1 (en) Tumor detection and monitoring
JP2002539765A (ja) 糞便サンプル調製のための方法
EP3724317A1 (fr) Détection d'analytes
EP3794139A1 (fr) Enrichissement et détection de méthylation spécifique à une séquence
US20190382824A1 (en) Negative-positive enrichment for nucleic acid detection
EP3507382A1 (fr) Analyse de la chromatine au moyen d'une enzyme de coupure
WO2018009702A1 (fr) Marqueurs de méthylation dans le traitement de la leucémie et leurs utilisations
US20180355437A1 (en) Plasma/serum target enrichment
EP4139926A2 (fr) Procédés permettant de détecter une lésion tissulaire, une maladie du greffon contre l'hôte, et des infections à l'aide d'un profilage d'adn acellulaire
US20190032116A1 (en) Sequence specific methylation enrichment and detection
US20190085318A1 (en) Solid phase negative enrichment
US20190002964A1 (en) Bodily fluid target enrichment
WO2018231945A1 (fr) Enrichissement négatif-positif pour la détection d'acides nucléiques
US20190071716A1 (en) Bodily fluid enrichment
CN108130359A (zh) 一种dna甲基化检测试剂盒及其应用
US20220127601A1 (en) Method of determining the origin of nucleic acids in a mixed sample
WO2017090543A1 (fr) Procédé d'analyse d'interaction entre adn
WO2020190613A1 (fr) Procédés de détection d'une maladie résiduelle minimale
WO2021055385A1 (fr) Dosage diagnostique pour le cancer
WO2023028546A1 (fr) Séquençage d'adn métagénomique sans contamination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18919343

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3100492

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018919343

Country of ref document: EP

Effective date: 20201216